JP2007509932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509932A5 JP2007509932A5 JP2006537956A JP2006537956A JP2007509932A5 JP 2007509932 A5 JP2007509932 A5 JP 2007509932A5 JP 2006537956 A JP2006537956 A JP 2006537956A JP 2006537956 A JP2006537956 A JP 2006537956A JP 2007509932 A5 JP2007509932 A5 JP 2007509932A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- pharmaceutical composition
- alkyl
- phenyl
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 3-ethoxy-4-methoxy-phenyl Chemical group 0.000 claims description 39
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 150000003431 steroids Chemical group 0.000 claims description 9
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 7
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 102000006495 integrins Human genes 0.000 claims description 7
- 108010044426 integrins Proteins 0.000 claims description 7
- 239000003900 neurotrophic factor Substances 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 239000000122 growth hormone Substances 0.000 claims description 6
- 239000003504 photosensitizing agent Substances 0.000 claims description 6
- 239000003075 phytoestrogen Substances 0.000 claims description 6
- 150000003180 prostaglandins Chemical class 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- 102000018997 Growth Hormone Human genes 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims description 3
- 229960003895 verteporfin Drugs 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229960001476 pentoxifylline Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 208000002780 macular degeneration Diseases 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- PRESUZGDRJSMNO-UHFFFAOYSA-N 2h-isoindol-4-amine Chemical compound NC1=CC=CC2=CNC=C12 PRESUZGDRJSMNO-UHFFFAOYSA-N 0.000 claims 1
- DHKAFTYWTCIWJX-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(N)=O)N1C(=O)C2=CC=CC=C2C1 DHKAFTYWTCIWJX-UHFFFAOYSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 208000035719 Maculopathy Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 235000013405 beer Nutrition 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FZEBPJBRDFXKIH-UHFFFAOYSA-N 2-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(C(=O)O)CC1=CC=CC=C1 FZEBPJBRDFXKIH-UHFFFAOYSA-N 0.000 description 1
- OUDWSJIHPUWLQE-UHFFFAOYSA-N 3-(3,4-diethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CC(O)=O)N1C(=O)C2=CC=CC=C2C1 OUDWSJIHPUWLQE-UHFFFAOYSA-N 0.000 description 1
- LGAZLBWJAFUDST-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(O)=O)N1C(=O)C2=CC=CC=C2C1 LGAZLBWJAFUDST-UHFFFAOYSA-N 0.000 description 1
- AAGICWVGIIDLTO-UHFFFAOYSA-N 3-(3-butoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCCCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 AAGICWVGIIDLTO-UHFFFAOYSA-N 0.000 description 1
- QYOSHOBNEQEKHZ-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 QYOSHOBNEQEKHZ-UHFFFAOYSA-N 0.000 description 1
- MQSVZMUVVKVXTQ-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(CC(=O)O)C1=CC=CC=C1 MQSVZMUVVKVXTQ-UHFFFAOYSA-N 0.000 description 1
- AIZIZEHVOQPQPO-UHFFFAOYSA-N 3-(4-methoxy-3-propoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 AIZIZEHVOQPQPO-UHFFFAOYSA-N 0.000 description 1
- KSFHVIUSXNPGHA-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=CC(OC)=CC=C1C(CC(O)=O)N1C(=O)C2=CC=CC=C2C1 KSFHVIUSXNPGHA-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940076002 angiogenesis modulator Drugs 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000006277 halobenzyl group Chemical group 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/699,110 US7776907B2 (en) | 2002-10-31 | 2003-10-30 | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| PCT/US2004/013253 WO2005044269A1 (en) | 2003-10-30 | 2004-04-28 | Cytokine inhibitory drugs for treatment of macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509932A JP2007509932A (ja) | 2007-04-19 |
| JP2007509932A5 true JP2007509932A5 (enExample) | 2007-06-07 |
Family
ID=34573277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006537956A Abandoned JP2007509932A (ja) | 2003-10-30 | 2004-04-28 | 黄斑変性症の治療用サイトカイン阻害薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7776907B2 (enExample) |
| EP (1) | EP1684756A4 (enExample) |
| JP (1) | JP2007509932A (enExample) |
| KR (1) | KR20060108695A (enExample) |
| CN (1) | CN1901909A (enExample) |
| AU (1) | AU2004286824A1 (enExample) |
| BR (1) | BRPI0415970A (enExample) |
| CA (1) | CA2543618A1 (enExample) |
| IL (1) | IL175311A0 (enExample) |
| WO (1) | WO2005044269A1 (enExample) |
| ZA (1) | ZA200603463B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| US20080070855A1 (en) * | 2006-09-20 | 2008-03-20 | James Pitzer Gills | Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes |
| MX2011012122A (es) | 2009-05-14 | 2012-02-28 | Tianjin Hemay Bio Tech Co Ltd | Derivados de tiofeno. |
| CN103402980B (zh) * | 2011-01-10 | 2016-06-29 | 细胞基因公司 | 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物 |
| US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
| IL303592A (en) * | 2020-12-11 | 2023-08-01 | Cognition Therapeutics Inc | Compositions for treating dry age-related macular degeneration (amd) |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| FR2649072B1 (fr) * | 1989-06-30 | 1991-11-29 | Design Agc Sarl | Conteneur en materiau thermoplastique moule en une seule piece et equipe d'une trompe verseuse |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5633947A (en) * | 1991-03-21 | 1997-05-27 | Thorn Emi Plc | Method and apparatus for fingerprint characterization and recognition using auto correlation pattern |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) * | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5675533A (en) * | 1994-09-26 | 1997-10-07 | Texas Instruments Incorporated | Semiconductor device |
| US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5596011A (en) | 1995-04-06 | 1997-01-21 | Repine; Karen M. | Method for the treatment of macular degeneration |
| IT1274549B (it) * | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
| US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| US5689579A (en) * | 1996-01-17 | 1997-11-18 | J.D. Carreker And Associates, Inc. | Rule-based circuit, method and system for performing item level reconciliation |
| NO310106B1 (no) * | 1996-03-13 | 2001-05-21 | Norsk Hydro As | Mikroporöse, krystallinske metallofosfatforbindelser, en fremgangsmåte for fremstilling og anvendelse derav |
| ATE418536T1 (de) * | 1996-08-12 | 2009-01-15 | Celgene Corp | Neue immunotherapeutische mittel und deren verwendung in der reduzierung von cytokinenspiegel |
| NZ502379A (en) | 1997-07-31 | 2002-10-25 | Celgene Corp | Substituted alkanohydroxamic acids and use in pharmaceuticals for reducing TNF-alpha levels |
| US6015803A (en) * | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| WO1999058096A2 (en) | 1998-05-11 | 1999-11-18 | Entremed, Inc. | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| DE19831217A1 (de) * | 1998-07-03 | 2000-01-05 | Schering Ag | Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik |
| US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) * | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| JP2000159761A (ja) | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
| US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| US6727364B2 (en) * | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| WO2003080048A1 (en) | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| EP1567148A4 (en) * | 2002-10-31 | 2010-09-15 | Celgene Corp | METHOD OF USE AND COMPOSITIONS WITH SELECTIVE CYTOKINE INHIBITORS FOR THE TREATMENT AND SUPPLEMENT OF MACULAR DEGENERATION |
| US7354948B2 (en) * | 2002-11-06 | 2008-04-08 | Celgene Corporation | Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| CN1738614A (zh) * | 2002-11-18 | 2006-02-22 | 细胞基因公司 | 包含(－)－3－(3,4－二甲氧基－苯基)－3－(1－氧代－1,3－二氢－异吲哚－2－基)－丙酰胺的组合物及其使用方法 |
| CA2511843C (en) * | 2002-12-30 | 2012-04-24 | Celgene Corporation | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| AU2004218364A1 (en) * | 2003-03-05 | 2004-09-16 | Celgene Corporation | Diphenylethylene compounds and uses thereof |
| NZ542671A (en) * | 2003-03-12 | 2008-12-24 | Celgene Corp | 7-Amido-isoindolyl compounds and their pharmaceutical uses |
| CA2518513C (en) * | 2003-03-12 | 2014-05-20 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
-
2003
- 2003-10-30 US US10/699,110 patent/US7776907B2/en not_active Expired - Fee Related
-
2004
- 2004-04-28 JP JP2006537956A patent/JP2007509932A/ja not_active Abandoned
- 2004-04-28 CA CA002543618A patent/CA2543618A1/en not_active Abandoned
- 2004-04-28 EP EP04750923A patent/EP1684756A4/en not_active Withdrawn
- 2004-04-28 US US10/576,140 patent/US20070207121A1/en not_active Abandoned
- 2004-04-28 CN CNA2004800394313A patent/CN1901909A/zh active Pending
- 2004-04-28 AU AU2004286824A patent/AU2004286824A1/en not_active Abandoned
- 2004-04-28 BR BRPI0415970-5A patent/BRPI0415970A/pt not_active IP Right Cessation
- 2004-04-28 WO PCT/US2004/013253 patent/WO2005044269A1/en not_active Ceased
- 2004-04-28 ZA ZA200603463A patent/ZA200603463B/en unknown
- 2004-04-28 KR KR1020067010464A patent/KR20060108695A/ko not_active Ceased
-
2006
- 2006-04-27 IL IL175311A patent/IL175311A0/en unknown
-
2010
- 2010-08-16 US US12/857,473 patent/US20110038832A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| JP2011506455A (ja) | 癌を処置するための治療薬の組み合わせ剤 | |
| US20230372275A1 (en) | Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases | |
| JP2007519649A5 (enExample) | ||
| MX2011005667A (es) | Combinacion farmaceutica que comprende un inhibidor de hsp90 y un inhibidor de mtor. | |
| JP5053503B2 (ja) | 過増殖状態を処置するための方法および組成物 | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| WO2013081154A1 (ja) | キナーゼ阻害剤の副作用低減剤 | |
| MX2007006992A (es) | Composiciones que comprenden moduladores pde4 y su uso para el tratamiento o prevencion de la inflamacion de las vias aereas. | |
| JP2007509932A5 (enExample) | ||
| JP2005508363A5 (enExample) | ||
| JP6687550B2 (ja) | 肝疾患又は肝機能異常を治療するためのアプレミラスト | |
| JP2006507307A (ja) | 黄斑変性を治療、予防および管理するための方法 | |
| US20030176488A1 (en) | Method for treating depression | |
| JP2006509743A5 (enExample) | ||
| AU2014284304B2 (en) | Method of treating neurodegenerative disorders | |
| AU2003285107B2 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
| JP4429732B2 (ja) | 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤 | |
| JP2007509932A (ja) | 黄斑変性症の治療用サイトカイン阻害薬 | |
| RU2007115092A (ru) | Аминоспиртовые производные | |
| CN117396505A (zh) | 治疗炎症的方法 | |
| EP1623741A2 (en) | Cannabinoid receptor ligands for hair growth modulation | |
| RU2000109558A (ru) | Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b | |
| JP2009143929A (ja) | 睡眠障害の予防・治療剤 | |
| JPWO2021080936A5 (enExample) |